Ignet

Gene Information

Gene symbol: EIF3A

Gene name: eukaryotic translation initiation factor 3, subunit A

HGNC ID: 3271

Synonyms: eIF3-theta, eIF3-p170, KIAA0139, eIF3a, TIF32

Related Genes

#	Gene Symbol	Number of hits
1	ABL1	1 hits
2	C19orf10	1 hits
3	CD40LG	1 hits
4	CSF2	1 hits
5	ECD	1 hits
6	ERBB2	1 hits
7	IL12A	1 hits
8	MET	1 hits
9	NEU1	1 hits

Related Sentences

#	PMID	Sentence
1	11046045	DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.
2	11313823	Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice.
3	11313823	Intramuscular vaccinations with 100 microg plasmid DNA encoding the extracellular domain of the Her-2/neu p185 (ECD) performed at the 6th, 12th, 18th and 24th week provided no significant protection, whereas those ECD plasmids in which the DNA coding for the immunomodulatory 163-171 (VQGEESNDK) nonapeptide of human IL1beta (ECD-IL1betap) had been inserted both delayed carcinogenesis and reduced tumor multiplicity.
4	15793299	We previously showed that a vaccine combining interleukin 12 and allogeneic p185(neu)-positive mammary carcinoma cells completely prevented multifocal mammary carcinogenesis in HER-2/neu transgenic mice.
5	17235320	We hypothesized that GA may enhance the efficacy of DNA vaccination, and investigated the therapeutic effect of the combination of GA and a DNA vaccine against HSP90 clients p185(neu) and Met.
6	17235320	Depletion of CD8(+) T cells eliminated most of the therapeutic efficacy; in contrast, depletion of CD4(+) T cells enhanced the therapeutic efficacy.
7	22841975	We developed several DNA-based vaccines encoding a BCR-ABL(p185) specific peptide and GM-CSF, and CD40-L, IL-27 or IL-12 and evaluated the preventive and therapeutic efficacy against a lethal challenge of syngeneic Ph(+) ALL in Balb/c mice.
8	22841975	Preventive immunization with the vaccine BCR-ABL/GM-CSF/IL-12 and the TLR-9 agonist dSLIM induced an innate and adaptive immune response mediated by NK-cells, CD4(+) T-cells and CD8(+) T-cells leading to a survival rate of 80%.
9	23772419	Protective immune responses were orchestrated by T cells and their cytokines, and effected by antibodies against HER-2 gene product p185.
10	23772419	The availability of cancer-prone mice carrying a human HER-2 transgene is now fostering the design of novel vaccines against human p185.
11	23772419	A further bridge toward human cancer was recently provided by novel immunodeficient models, like Rag2(-/-);Il2rg(-/-) mice, which are permissive for metastatic spread of human HER-2+ cancer cells and can be engrafted with a functional human immune system, allowing for the first time the study of vaccines against oncoantigens to elicit human immune responses against human cancer cells in vivo.
12	23772419	Protective immune responses were orchestrated by T cells and their cytokines, and effected by antibodies against HER-2 gene product p185.
13	23772419	The availability of cancer-prone mice carrying a human HER-2 transgene is now fostering the design of novel vaccines against human p185.
14	23772419	A further bridge toward human cancer was recently provided by novel immunodeficient models, like Rag2(-/-);Il2rg(-/-) mice, which are permissive for metastatic spread of human HER-2+ cancer cells and can be engrafted with a functional human immune system, allowing for the first time the study of vaccines against oncoantigens to elicit human immune responses against human cancer cells in vivo.
15	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
16	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
17	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
18	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
19	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
20	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
21	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
22	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
23	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
24	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
25	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
26	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
27	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
28	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
29	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
30	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
31	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
32	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
33	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
34	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
35	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
36	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
37	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
38	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
39	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
40	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
41	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
42	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
43	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
44	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
45	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
46	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
47	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
48	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
49	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
50	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
51	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
52	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
53	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
54	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
55	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
56	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
57	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
58	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
59	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
60	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
61	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
62	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
63	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
64	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
65	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
66	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
67	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
68	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
69	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
70	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.
71	24462404	To develop a novel live vaccine against M. bovis, two attenuated M. bovis strains, P150 and P180, were tested in calves for protection against challenge with the virulent M. bovis parental strain.
72	24462404	Twenty calves were divided into four groups of five calves each that were designated as the P150, P180, positive control (PC), and negative control (NC) groups.
73	24462404	Each calf in the P150 and P180 groups was immunized with 10(9)CFU of P150 or P180, respectively, via the nasal cavity, and the PC and NC groups received the mock inoculation.
74	24462404	The P150, P180, and PC calves were challenged with a dose of 10(10)CFU of virulent M. bovis by intratracheal injection on 3 consecutive days.
75	24462404	The P150 and P180 immunizations caused no clinical abnormality, and did not affect daily weight gain.
76	24462404	The post-inoculation neutrophil ratio and serum levels of IgG and IFN-β significantly increased in the P150, P180, and PC calves, whereas the serum levels of IgA and TNF-α did not.
77	24462404	Bovis infection, whereas immunization with P150 or P180 provided efficacious protection.
78	24462404	Based on the scores for gross pathology and lung pathology, the protection rates of the P150 and P180 immunizations were 87.7% and 70.8%, respectively.